Clinical trials: Non Metastatic Breast Cancer
Neoplasms
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer
- Trial name
- NCT05712889
- Testing
- VIP236 (Q3W), VIP236 (Q2W)
- Where
- 6 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- Vincerx Pharma, Inc.
Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease
The goal of this phase II clinical trial] is to analyze the efficacy of patritumab deruxtecan (HER3-DXd) in patients with metastatic breast cancer (MBC) or advanced non-small cell lung cancer (aNSCLC) with active brain metastases…
- Conditions
- Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult
- Trial name
- TUXEDO-3 (NCT05865990)
- Testing
- Patritumab deruxtecan
- Where
- 8 sites in Austria, Spain
- Volunteers
- 63 people
- Sponsor
- MedSIR
Neutropenia, Breast Cancer
A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
The purpose of this study is to assess pegfilgrastim starting with the first cycle versus secondary prophylaxis on neutropenic events (including neutropenia +/- fever, dose delays, dose reductions, and hospitalizations) in older…
- Conditions
- Neutropenia, Breast Cancer, Lung Cancer, Non-Hodgkin's Lymphoma
- Trial name
- NCT00277160
- Testing
- Neulasta (pegfilgrastim)
- Volunteers
- 852 people
- Sponsor
- Amgen
Breast Cancer, Leukemia
Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006225
- Testing
- filgrastim, recombinant flt3 ligand, recombinant human thrombopoietin
- Where
- United States
- Sponsor
- Northwestern University
Metastatic Breast Cancer
PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)
This study is an open-label,non randomized, multi-center, phase 1/2b (dose escalation followed by expansion part) study evaluating clinical safety, efficacy and pharmacokinetics of PQR309 in combination with standard dose of…
- Trial name
- NCT02723877
- Testing
- PQR309, Eribulin
- Where
- 5 sites in Spain, United Kingdom
- Volunteers
- 41 people
- Sponsor
- PIQUR Therapeutics AG
Endocrine Tumors, Non-Small Cell Lung Cancer
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible.
- Conditions
- Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03412877
- Testing
- Cyclophosphamide, Fludarabine, Aldesleukin
- Where
- United States
- Volunteers
- 285 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Lymphoma
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Filgrastim and stem cell factor may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's…
- Trial name
- NCT00005993
- Testing
- aldesleukin, filgrastim, recombinant human stem cell factor
- Sponsor
- Masonic Cancer Center, University of Minnesota
Malignant Neoplasm of Breast, Hodgkin Disease
Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality
Identify the best combination of predictive variables that influence ionizing radiation dose and improved image quality through analysis and quantification of PET-CT images in simulators and patients.
- Conditions
- Malignant Neoplasm of Breast, Hodgkin Disease, Non-Hodgkin Lymphoma, Follicular (Nodular), Malignant Neoplasm of Bronchus and Lung
- Trial name
- pet-ct (NCT02378337)
- Testing
- Image quantify
- Where
- Brazil
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- Hospital Sao Rafael
Breast Neoplasms
The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
The main objective of the trial is to assess the efficacy of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in patients with HR+/ HER2- advanced or metastatic breast cancer and…
- Trial name
- NCT03659136
- Testing
- Xentuzumab, Everolimus, Exemestane
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 103 people
- Sponsor
- Boehringer Ingelheim
Cancer
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, ondansetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients undergoing a stem cell transplant.
- Trial name
- NCT00248547
- Testing
- aprepitant, dexamethasone, ondansetron
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer, Artificial Intelligence
Prediction of Non-sentinel Lymph Node Metastatic Status of Breast Cancer Based on Pathology-MRI Images
The goal of this observational study is to develop an artificial intelligence model based on pathology and magnetic resonance imaging (MRI) images to predict the metastatic status of non-sentinel lymph nodes in patients with…
- Conditions
- Breast Cancer, Artificial Intelligence, Lymph Node Metastasis, Digital Pathology
- Trial name
- NCT06510738
- Volunteers
- 700 people
- Sponsor
- Yunnan Cancer Hospital
Breast Cancer
Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, methotrexate, and prednisolone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00687648
- Testing
- anastrozole, cyclophosphamide, exemestane
- Where
- Singapore
- Volunteers
- 70 people
- Sponsor
- National Cancer Centre, Singapore
Hematological Neoplasms, Non-Hodgkin's Lymphoma
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
This is a Phase 1, open-label, multicenter, randomized, 2-stage crossover study consisting of 2 phases: Stage I - Pharmacokinetics (Bioequivalence), with an Extension Stage II - Pharmacokinetics (Food Effect) with an Extension…
- Conditions
- Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma
- Trial name
- NCT02223052
- Testing
- CC-486, Vidaza
- Where
- 10 sites in United States
- Volunteers
- 89 people
- Sponsor
- Celgene
Solid Tumor, Adult, Advanced Solid Tumor
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with…
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer
- Trial name
- NCT05864144
- Testing
- SNS-101 (anti-VISTA), Cemiplimab
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sensei Biotherapeutics, Inc.
Melanoma, Ovarian Cancer
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
This is a Phase I, multi-center, multiple ascending dose study to evaluate the clinical safety and immune response of IDC-G305 when injected intramuscularly in patients with unresectable or metastatic cancer.
- Conditions
- Melanoma, Ovarian Cancer, Sarcoma, Non-small Cell Lung Cancer
- Trial name
- NCT02015416
- Testing
- IDC-G305
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Liver Metastasis, Pelvic Cancer
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
This multi-center photodynamic therapy study plans to treat patients with large tumors in any superficial location, sarcoma, tumors of oral/oro-pharyngeal cavity, tumors with extensive pelvic involvement, or liver metastasis.
- Conditions
- Liver Metastasis, Pelvic Cancer, Head and Neck Cancer, Sarcoma
- Trial name
- NCT00028405
- Testing
- LS 11(Taporfin Sodium), Lumaflex Light Delivery Catheter
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Light Sciences LLC
Breast Cancer, Metastatic Breast Cancer
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
The purpose of this study is to determine whether lucitanib is safe and effective in the treatment of patients with FGF aberrant metastatic breast cancer, as well as in the treatment of patients with biomarker negative (FGF…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, MBC, HER2 Positive
- Trial name
- NCT02202746
- Testing
- Lucitanib
- Where
- 33 sites in United States
- Volunteers
- 178 people
- Sponsor
- Clovis Oncology, Inc.
Breast Cancer, Low Bone Mineral Density
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer
The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.
- Conditions
- Breast Cancer, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00089661
- Testing
- AMG 162 / Denosumab
- Volunteers
- 252 people
- Sponsor
- Amgen
Breast Cancer, Non Small Cell Lung Cancer
Metronomic Oral Vinorelbine in Patients With Metastatic Tumors
Patients with recurrent or metastatic solid tumors receive oral vinorelbine at one of three different doses (30 or 40 or 50 mg).
- Conditions
- Breast Cancer, Non Small Cell Lung Cancer, Prostate Cancer
- Trial name
- NCT00278070
- Testing
- vinorelbine oral formulation
- Where
- 11 sites in Greece
- Sponsor
- Hellenic Cooperative Oncology Group
Cancer
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
RATIONALE: Giving donor natural killer cells to patients who have undergone donor bone marrow transplant may make the transplant work better and keep cancer cells from coming back.
- Trial name
- NCT00569283
- Testing
- therapeutic allogeneic lymphocytes
- Where
- 2 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- Asan Medical Center